Overview
- The University of Miami team reported Monday in EMBO Molecular Medicine that metformin raised the exercise‑associated metabolite Lac‑Phe to post‑workout levels in men with prostate cancer.
- The increase emerged without exercise and persisted after patients started androgen‑deprivation therapy.
- In the trial cohort, most men on metformin maintained or lost weight over six months of hormone treatment.
- Higher Lac‑Phe did not correspond to anticancer benefit, showing no correlation with PSA changes.
- The small study drew on the BIMET‑1 cohort and an added patient set, and the authors call for larger trials to test clinical impact and clarify the roles of Lac‑Phe and GDF‑15.